Horizon Clinical Research Group

The trials here

What the 21 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease4 trials
• Asthma2 trials
• Bronchiectasis2 trials
• COPD2 trials
• Epilepsy2 trials
• Idiopathic pulmonary fibrosis2 trials
• Lewy body dementia2 trials
• Parkinson disease2 trials
• Graves' disease1 trial
• High blood pressure1 trial
• Lung cancer1 trial
• Obesity1 trial
• and 2 more

Phase

• Phase 39 trials
• Phase 28 trials
• Phase 2/33 trials

Status

• Recruiting10 trials
• Active, not recruiting5 trials
• Completed3 trials
• Enrolling by invitation2 trials
• Not yet recruiting1 trial

Lead sponsor

• ACADIA Pharmaceuticals Inc.4 trials
• Biohaven Therapeutics Ltd.2 trials
• Boehringer Ingelheim2 trials
• Pfizer2 trials
• Cerevance1 trial
• and 10 more

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

  NCT07783802· Phase 2· Eli Lilly and Company· Source

  Contact: Fadi Alameddine (principal investigator)

• Recruiting

  To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

  NCT07684820· Phase 2· Expedition Therapeutics, Inc· Source

  Contact: Lucia Sabido

• Recruiting

  Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

  NCT07671911· Phase 3· Trevi Therapeutics· Source

  Contact: Paula Buckley

• Recruiting

  Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

  NCT07284602· Phase 3· PureTech· Source

  Contact: Dileep Puppala, MD

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  NCT07363694· Phase 2/3· Pfizer· Source

• Recruiting

  Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

  NCT07095465· Phase 3· ACADIA Pharmaceuticals Inc.· Source

  Contact: Kristin Kidd

• Recruiting

  Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

  NCT07029581· Phase 2· ACADIA Pharmaceuticals Inc.· Source

  Contact: Kristin Kidd

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

  NCT06977581· Phase 2· Pfizer· Source

• Active, not recruiting

  To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

  NCT06553027· Phase 3· Cerevance· Source

• Active, not recruiting

  An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

  NCT06625398· Phase 3· Viridian Therapeutics, Inc.· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

  NCT06540833· Phase 2· Intra-Cellular Therapies, Inc.· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Biohaven Therapeutics Ltd.· Source

• Active, not recruiting

  Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06309966· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Enrolling by invitation

  ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

  NCT06194799· Phase 3· ACADIA Pharmaceuticals Inc.· Source

• Recruiting

  ACP-204 in Adults With Alzheimer's Disease Psychosis

  NCT06159673· Phase 2/3· ACADIA Pharmaceuticals Inc.· Source

  Contact: Christine Murphy

• Active, not recruiting

  Screening for High Frequency Malignant Disease

  NCT05117840· Guardant Health, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease3 recruiting
• COPD2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Lewy body dementia2 recruiting
• Asthma1 recruiting
• Bronchiectasis1 recruiting
• Epilepsy1 recruiting
• High blood pressure1 recruiting
• Obesity1 recruiting
• Schizophrenia1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

  NCT06881836· Phase 2· Ono Pharmaceutical Co., Ltd.· Source

• Completed

  A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

  NCT06664619· Phase 3· Teva Branded Pharmaceutical Products R&D LLC· Source

• Completed

  Early Parkinson's Disease Monotherapy With CVN424

  NCT06006247· Phase 2· Cerevance Beta, Inc.· Source